Tirzepatide + Retatrutide + Placebo
Phase 3Recruiting 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Metabolic Dysfunction-Associated Steatotic Liver Disease
Conditions
Metabolic Dysfunction-Associated Steatotic Liver Disease
Trial Timeline
Oct 15, 2025 → Aug 1, 2032
NCT ID
NCT07165028About Tirzepatide + Retatrutide + Placebo
Tirzepatide + Retatrutide + Placebo is a phase 3 stage product being developed by Eli Lilly for Metabolic Dysfunction-Associated Steatotic Liver Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07165028. Target conditions include Metabolic Dysfunction-Associated Steatotic Liver Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07165028 | Phase 3 | Recruiting |
Competing Products
20 competing products in Metabolic Dysfunction-Associated Steatotic Liver Disease